SYSTEMATIC REVIEW OF HEALTH ECONOMIC EVALUATIONS OF RARE DISEASES IN MEXICO
Author(s)
Osvaldo Diaz Alvarez1, María Paula Buritica, Master in Science2, Herman Soto, Sr., MSc3, Victor E. Martinez, Master in Science4, Johana Rivera Martínez, Bachelor in science5;
1AstraZeneca, CDMX, Mexico, 2Astrazeneca, MEXICO, Mexico, 3AMETESA, Iztapalapa, Mexico, 4HS Estudios Farmacoeconómicos, Mexico city, Mexico, 5HS Estudios Farmacoeconómicos, CDMX, Mexico
1AstraZeneca, CDMX, Mexico, 2Astrazeneca, MEXICO, Mexico, 3AMETESA, Iztapalapa, Mexico, 4HS Estudios Farmacoeconómicos, Mexico city, Mexico, 5HS Estudios Farmacoeconómicos, CDMX, Mexico
OBJECTIVES: To provide an overview of published studies related to health economic evaluations performed from the perspective of Mexico.
METHODS: A systematic review (SR) was carried following the methodology proposed by the Cochrane Collaboration. The review included published studies concerning both full economic evaluations (cost effectiveness analysis (CEA), cost utility analysis (CUA), cost benefit (CBA) and minimization of costs (MCA)) and other health economic analysis (budget impact analysis (BIA), economic burden of disease (EBoD), cost consequence analysis and cost analysis). The studies should be conducted from the perspective of Mexico, evaluating patients with rare diseases. Full text publications and congress abstracts, published in English and Spanish, were included. The SR was carried out in the following databases: PubMed, Cochrane Central Library, CRD York and LILACS, in addition a manual search in the ISPOR platform and in web browser. The search was carried out until 29 July 2025.
RESULTS: A total of 14 studies were included. Four evaluated patients with pulmonary arterial hypertension, 4 type A and B hemophilia, 2 hereditary transthyretin-associated amyloidosis, and one publication for type 1 Gaucher disease, neonatal congenital hypothyroidism, osteosarcoma, and retinitis pigmentosa, respectively. Six publications correspond to a EBoD, 4 correspond to BIA, 2 to CEA, and 1 for a CMA and a SR of CEA in osteosarcoma. It is important to note that 9 publications were congress abstracts and 5 were full text publications.
CONCLUSIONS: The studies published concerning economic evaluations in Mexico are limited, being the majority published as congress abstracts. Generating evidence in terms of health economics concerning rare diseases could benefit decision makers in Mexico to estimate the economic impact of rare diseases, as well as the economic efficiency of the drugs intended for these diseases.
METHODS: A systematic review (SR) was carried following the methodology proposed by the Cochrane Collaboration. The review included published studies concerning both full economic evaluations (cost effectiveness analysis (CEA), cost utility analysis (CUA), cost benefit (CBA) and minimization of costs (MCA)) and other health economic analysis (budget impact analysis (BIA), economic burden of disease (EBoD), cost consequence analysis and cost analysis). The studies should be conducted from the perspective of Mexico, evaluating patients with rare diseases. Full text publications and congress abstracts, published in English and Spanish, were included. The SR was carried out in the following databases: PubMed, Cochrane Central Library, CRD York and LILACS, in addition a manual search in the ISPOR platform and in web browser. The search was carried out until 29 July 2025.
RESULTS: A total of 14 studies were included. Four evaluated patients with pulmonary arterial hypertension, 4 type A and B hemophilia, 2 hereditary transthyretin-associated amyloidosis, and one publication for type 1 Gaucher disease, neonatal congenital hypothyroidism, osteosarcoma, and retinitis pigmentosa, respectively. Six publications correspond to a EBoD, 4 correspond to BIA, 2 to CEA, and 1 for a CMA and a SR of CEA in osteosarcoma. It is important to note that 9 publications were congress abstracts and 5 were full text publications.
CONCLUSIONS: The studies published concerning economic evaluations in Mexico are limited, being the majority published as congress abstracts. Generating evidence in terms of health economics concerning rare diseases could benefit decision makers in Mexico to estimate the economic impact of rare diseases, as well as the economic efficiency of the drugs intended for these diseases.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE386
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Rare & Orphan Diseases